Emerging pipeline drugs for hepatitis B infection

Expert Opinion on Emerging Drugs

Volumn 16, Issue 4, 2011, Pages 713-729

  Cox, Natravis ^a   Tillmann, Hans ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiviral therapy; Chronic hepatitis B; Combination therapy; Quantitative HBsAg; Vaccines

Indexed keywords

ACTIMMUN; ADEFOVIR; AFLATOXIN; ALPHA1 INTERFERON; AMDOXOVIR; BAY 41 4109; CARRIER PROTEIN; CLEVUDINE; DNA; EMTRICITABINE; ENTECAVIR; GAMMA1B INTERFERON; HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; NITAZOXANIDE; NUCLEOSIDE; NUCLEOTIDE; PEGINTERFERON ALPHA2B; PLACEBO; PROTEIN CTY107; PROTEIN MYRCLUDEX; PYRIMIDINE DERIVATIVE; RECOMBINANT INTERFERON; RECOMBINANT INTERLEUKIN 7; REP 9AC; TELBIVUDINE; TENOFOVIR; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIDARABINE;

ABDOMINAL PAIN; ADD ON THERAPY; ANTIVIRAL THERAPY; CELL MATURATION; CLINICAL TRIAL (TOPIC); CREATINE KINASE BLOOD LEVEL; DELTA AGENT HEPATITIS; DIARRHEA; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; FATIGUE; FIBROSIS; FOLLOW UP; HEADACHE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IN VIVO STUDY; INFLAMMATION; KIDNEY DISEASE; LACTIC ACIDOSIS; LIVER BIOPSY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MONOTHERAPY; MORTALITY; MYOPATHY; NONHUMAN; OSTEOPOROSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SEROCONVERSION; T LYMPHOCYTE; UPPER RESPIRATORY TRACT INFECTION; VIRUS LOAD;

ADENINE; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUGS, INVESTIGATIONAL; GUANINE; HEPATITIS B ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; PHOSPHONIC ACIDS; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 84555196611     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.2011.646260     Document Type: Review

References (100)

1. Hepatitis B vaccines: WHO position paper. WHO Wkly Epidemiol Rec 2009;84:405-20
2. Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45:529-38 (Pubitemid 44307383)
3. Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 2003;39(SUPPL. 1):S64-9 (Pubitemid 37222649)
4. Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect 2010;118:818-24
5. Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74
6. Fwu CW, Chien YC, Kirk GD, et al. Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study. J Natl Cancer Inst 2009;101:1019-27
7. Wong GL, Wong VW, Choi PC, et al. Clinical factors associated with liver stiffness in hepatitis B e antigen-positive chronic hepatitis B patients. Clin Gastroenterol Hepatol 2009;7:227-33
8. Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996;334:1422-7 (Pubitemid 26157437)
9. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73 (Pubitemid 43042691)
10. Liu J, Lee M H, Batrla-Utermann R, et al. Quantitative hepatitis B surface antigen levels are significant independent predictors of HBV DNA and HbsAG seroclearance in chronic hepatitis B. Hepatology 2011;54:480A
11. Levrero M, Pollicino T, Petersen J, et al. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009;51:581-92
12. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004;10:S74-85 (Pubitemid 39406104)
13. Simonetti J, Bulkow L, McMahon BJ, et al. Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus. Hepatology 2010;51:1531-7
14. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-2
15. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-42
16. Sun X, Qin W, Zhou R, et al. Effect of conventional interferon-alpha in patients with HBeAg-positive chronic hepatitis B: a systematic review and meta-analysis. J Evid Based Med 2010;3:220-5
17. Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003;10:298-305 (Pubitemid 36801917)
18. Yu HB, Liu EQ, Lu SM, Zhao SH. Treatment with peginterferon versus interferon in Chinese patients with hepatitis B. Biomed Pharmacother 2010;64:559-64
19. Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005;352:2682-95 (Pubitemid 41007823)
20. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004;351:1206-17 (Pubitemid 39296307)
21. Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005;365:123-9 (Pubitemid 40091801)
22. Liaw Y, Xie Q, Han K, et al. Shorter duration and lower dose of peginterferon alfa-2a thereapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 muG: Neptune study. Hepatology 2010;52:429A
23. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999;341:1256-63 (Pubitemid 29489740)
24. Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-80 (Pubitemid 30452590)
25. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32 (Pubitemid 32496991)
26. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125:1714-22 (Pubitemid 37500436)
27. Puchhammer-Stockl E, Mandl CW, Kletzmayr J, et al. Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy. J Infect Dis 2000;181:2063-6 (Pubitemid 30416176)
28. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003;348:808-16 (Pubitemid 36245757)
29. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003;348:800-7 (Pubitemid 36245756)
30. Lampertico P, Vigano M, Facchetti F, et al. Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. Nephrol Dial Transplant 2011;26:2037-41
31. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006;354:1001-10 (Pubitemid 43357804)
32. Tenney DJ, Rose RE, Baldick CJ, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009;49:1503-14
33. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006;354:1011-20 (Pubitemid 43357805)
34. Chang TT, Chao YC, Gorbakov VV, et al. Results of up to 2 years of entecavir vs lamivudine therapy in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2009;16:784-9
35. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006;44:1656-65 (Pubitemid 44953670)
36. Chang TT, Gish RG, Hadziyannis SJ, et al. A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. Gastroenterology 2005;129:1198-209 (Pubitemid 41446860)
37. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009;50:2001-6
38. Damerow H, Yuen L, Wiegand J, et al. Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol 2010;82:1850-8
39. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007;357:2576-88 (Pubitemid 350294224)
40. Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009;136:486-95
41. Zeuzem S, Gane E, Liaw YF, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol 2009;51:11-20
42. Goncalves J, Laeufle R, Avila C, et al. Increased risk with combination of telbivudine and pegylated-interferon Alfa-2A in study CLDT600A2406, compared to uncommon rate with telbivudine monotherapy from Novartis Global Database. J Hepatol 2009;50:S329-30
43. Garcia G, Smith CI, Weissberg JI, et al. Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. A randomized, double-blinded, placebo-controlled trial. Ann Intern Med 1987;107:278-85
44. Marcellin P, Buti M, Gane EJ, et al. Five Years of Treatment with Tenofovir DF (TDF) for Chronic Hepatitis B (CHB) infection is associated with sustained viral suppression and significant regression of histological fibrosis and cirrhosis. Hepatology 2011;54:1011A
45. Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005;10:727-34 (Pubitemid 41376852)
46. Verhelst D, Monge M, Meynard JL, et al. Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis 2002;40:1331-3 (Pubitemid 35403147)
47. Wedemeyer H, Yurdaydin C, Dalekos GN, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011;364:322-31
48. Piccolo P, Lenci I, Demelia L, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009;14:1165-74
49. Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006;44:675-84 (Pubitemid 44433724)
50. Marcellin P, Martinot-Peignoux M, Lapalus M, et al. High rate of HbsAg loss predicted by baseline HBsAg titer and decline on treatment in chronic hepatitis B patients receiving pegylated interferon plus tenofovir combination therapy. Hepatology 2011;54:1010A
51. Sarin SK, Sood A, Kumar M, et al. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007;102:96-104 (Pubitemid 46072048)
52. Ning Q, Han M, Sun Y, et al. Patients with HBeAg-Positive Chronic Hepatitis B (CHB) with a maintained virological response to entecavir acheived HBsAg clearance when switched to peginterferon Alfa-2A therapy (OSST Study). Hepatology 2011;54:1010A
53. Ouzan D, Guillaume P, Joly H, et al. Add-on peg-interferon to a stable nucleoside regimen led to loss of HBsAg in chronic HBeAg negative patients. Hepatology 2011;54:1015A
54. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005;129:528-36 (Pubitemid 41096641)
55. Carey I, Harrison PM. Monotherapy versus combination therapy for the treatment of chronic hepatitis B. Expert Opin Investig Drugs 2009;18:1655-66
56. Wiegand J, Wedemeyer H, Finger A, et al. A decline in hepatitis B virus surface antigen (hbsag) predicts clearance, but does not correlate with quantitative hbeag or HBV DNA levels. Antivir Ther 2008;13:547-54 (Pubitemid 352016717)
57. Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009;49:1141-50
58. Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010;52:454-61
59. Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009;49:1151-7
60. Tziomalos K. Effect of antiviral treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis B. World J Hepatol 2010;2:91-3
61. Zhang QQ, An X, Liu YH, et al. Long-term nucleos(t)ide analogues therapy for adults with chronic hepatitis B reduces the risk of long-term complications: a meta-analysis. Virol J 2011;8:72
62. Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004;351:1521-31
63. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011;54:91-100
64. Leung N, Gish RG, Wang C, et al. A randomized, double-blind comparison of 3 doses of emtricitabine in patients with chronic hepatitis B given 48 weeks of treatment. Hepatology 2001;34:349A
65. Yoo BC, Kim JH, Chung YH, et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007;45:1172-8
66. Lau GK, Leung N. Forty-eight weeks treatment with clevudine 30 mg qd versus lamivudine 100 mg qd for chronic hepatitis B infection: a double-blind randomized study. Korean J Hepatol 2010;16:315-20
67. Seigneres B, Pichoud C, Martin P, et al. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology 2002;36:710-22 (Pubitemid 34977183)
68. Yuen MF, Kim J, Kim CR, et al. A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B. Antivir Ther 2006;11:977-83 (Pubitemid 44955173)
69. Yuen MF, Han KH, Um SH, et al. Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease. Hepatology 2010;51:767-76
70. Lai C, Ahn S, Lee K, et al. A phase IIB study of the efficacy and safety of LB80380 vs entecavir in treatment-naive patients with chronic hepatitis B. J Hepatol 2011;54:S535-46
71. Michalak TI, Zhang H, Churchill ND, et al. Profound antiviral effect of oral administration of MIV-210 on chronic hepadnaviral infection in a woodchuck model of hepatitis B. Antimicrob Agents Chemother 2009;53:3803-14
72. Lee HW, Lee JI, Um SH, et al. Combination therapy of thymosin alpha-1 and lamivudine for HbeAg positive chronic hepatitis B: A prospective randomized, comparative pilot study. J Gastroenterol Hepatol 2008;23:729-35 (Pubitemid 351519437)
73. Yang YF, Zhao W, Zhong YD, et al. Comparison of the efficacy of thymosin alpha-1 and interferon alpha in the treatment of chronic hepatitis B: a meta-analysis. Antiviral Res 2008;77:136-41
74. Wu GY, Zheng XJ, Yin CC, et al. Inhibition of hepatitis B virus replication by Bay 41-4109 and its association with nucleocapsid disassembly. J Chemother 2008;20:458-67
75. Stray SJ, Zlotnick A. BAY 41-4109 has multiple effects on Hepatitis B virus capsid assembly. J Mol Recognit 2006;19:542-8 (Pubitemid 46024897)
76. Schieck A, Muller T, Schulze A, et al. Solid-phase synthesis of the lipopeptide Myr-HBVpreS/2-78, a hepatitis B virus entry inhibitor. Molecules 2010;15:4773-83
77. Petersen J, Dandri M, Mier W, et al. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 2008;26:335-41 (Pubitemid 351355128)
78. Gaur AH, Bagga B, Barman S, et al. Intravenous zanamivir for oseltamivir-resistant 2009 H1N1 influenza. N Engl J Med 2010;362:88-9
79. Troia-Cancio P, Asmuth DM. Lessons from maraviroc clinical trials. Expert Rev Anti Infect Ther 2011;9:649-51
80. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011;378:73-85
81. Lutgehetmann M, Petersen J, Volz T, et al. The entry inhibitor Myrcludex-B efficiently blocks viral spreading in vivo in human liver Chimeric UPA/SCID mice previously infected with hepatitis B virus. Hepatology 2011;54:372A
82. Al-Mahtab M, Bazinet M, Vaillant A. REP 9AC is a potent HBsAg release inhibitor which clears serum HBsAg and elicits svrs in patients with chronic hepatitis B. J Hepatol 2011;54:S34
83. Bock CT, Tillmann HL, Maschek HJ, et al. A preS mutation isolated from a patient with chronic hepatitis B infection leads to virus retention and misassembly. Gastroenterology 1997;113:1976-82 (Pubitemid 27512157)
84. Noordeen F, Vaillant A, Juteau JM, et al. Preclinical development of the amphipathic DNA polymer REP 9AC for the treatment of HBV infection. Global Antivir J 2007;3:26
85. Menne S, Tennant B, Liu KH, et al. Anti-viral efficacy and induction of an antibody response against surface antigen with the TLR7 agonist GS-9620 in the woodchuck model of chronic HBV infection. J Hepatol 2011;54:S441
86. Lanford R, Guerra B, Chavez D, et al. Therapeutic efficacy of the TLR7 agonist GS-9620 for HBV chronic infection in chimpanzees. 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011). Berlin. March 30-April 3. Abstract 384
87. Vicari AP, Schmalbach T, Lekstrom-Himes J, et al. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther 2007;12:741-51 (Pubitemid 47235488)
88. McHutchison JG, Bacon BR, Gordon SC, et al. Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus. Hepatology 2007;46:1341-9 (Pubitemid 350155515)
89. Korba BE, Montero AB, Farrar K, et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 2008;77:56-63
90. Stachulski AV, Pidathala C, Row EC, et al. Thiazolides as novel antiviral agents. 1. Inhibition of hepatitis B virus replication. J Med Chem 2011;54:4119-32
91. Parvez MK, Sehgal D, Sarin SK, et al. Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma. World J Gastroenterol 2006;12:3006-14 (Pubitemid 43811076)
92. Carreno V, Moreno A, Galiana F, Bartolome FJ. Alpha-and gamma-interferon versus alpha-interferon alone in chronic hepatitis B. A randomized controlled study. J Hepatol 1993;17:321-5 (Pubitemid 23134928)
93. Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-7 (Pubitemid 47127032)
94. Lui YY, Tsoi KK, Wong VW, et al. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Antivir Ther 2010;15:145-55
95. Feld JJ, Wong DK, Heathcote EJ. Endpoints of therapy in chronic hepatitis B. Hepatology 2009;49:S96-S102
96. Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-500
97. Marcellin P, Buti M, Krastev Z, et al. A randomized, double-blind, comparison of Tenofovir DF (TDF) versus Adefovir Diolvoxil (ADV) for the treatment of HBeAg-negative Chronic Hepatitis B (CHB): Study GS-US-174 0102. Hepatology 2007;46:290A
98. Marcellin P, Brunetto M, Bonino F, et al. Long-term Follow-up of HbsAg clearance in patients with HBeAG-negative CHB treated with PEG-Interferon Alfa-2a: increase in HBsAg clearance rate from 3% 6 months post-treatment to 8% after 3 years. Hepatology 2007;46:673A
99. Heathcote EJ, Gane E, DeMan R, et al. A Randomized, double-blind, comparison of Tenofovir DF (TDF) versus Adefovir Dipivoxil (ADV) for the treatment of HBeAg positive Chronic Hepatitis B (CHB): Study GS-US-174-0103. Hepatology 2007;46:861A
100. Lai CL, Gane E, Liaw YF, et al. Telvibudine (LDT) vs. lamivudine for Chronic Hepatitis B: first-year results from the international phase III globe trial. Hepatology 2005;42:748A